RxDoctor Payments Data

Jennifer Lynch

Family · Hartsville, SCNPI 1740663038

Payments from drug & device makers

$9,109in general payments, 2019–2025

Across 531 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Abbott$452
  • Lilly USA, LLC$443
  • Amgen$393
  • Novo Nordisk$346
  • Otsuka America Pharmaceutical, Inc.$335
  • plus $5K from 53 others

What the payments were for

  • Consulting fees$2102%
  • Food & beverage$8,88998%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie180$2,623
Abbott27$452
Lilly USA, LLC32$443
Amgen23$393
Novo Nordisk18$346
Otsuka America Pharmaceutical, Inc.19$335
Lundbeck LLC16$317
Novartis15$295
Pfizer16$291
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$286
Alnylam Pharmaceuticals Inc.3$272
Biogen4$258
AstraZeneca12$216
Teva Pharmaceuticals USA, Inc.8$193
Paratek Pharmaceuticals, Inc.12$180
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$173
Biohaven Pharmaceuticals, Inc.12$142
Axsome Therapeutics, Inc.6$125
Boehringer Ingelheim6$121
Biohaven Pharmaceutical Holding Company Ltd.8$118
Corcept Therapeutics5$99
Dexcom, Inc.5$90
Xeris Pharmaceuticals, Inc.5$89
TG Therapeutics, Inc.4$89
GSK5$88
Regeneron Healthcare Solutions, Inc.4$81
Astellas Pharma US Inc4$73
Tersera Therapeutics LLC3$68
Ardelyx, Inc.3$58
Averitas Pharma Inc.2$54
CSL Behring2$50
Acadia Pharmaceuticals Inc2$44
Bayer3$44
Argenx US, Inc.2$40
Takeda Pharmaceuticals U.S.A., Inc.2$40
Merck3$38
Mallinckrodt Hospital Products Inc.2$36
Supernus Pharmaceuticals, Inc.2$33
Verona Pharma, Inc.2$33
Jazz Pharmaceuticals Inc.2$28
Eisai Inc.1$25
Daiichi Sankyo Inc.1$24
Neurocrine Biosciences, Inc.1$23
KCI USA, Inc.1$23
Verity Pharmaceuticals Inc.1$23
UCB, Inc.1$23
Alkermes, Inc.1$22
Genentech USA, Inc.1$20
Sumitomo Pharma America, Inc.1$19
Celltrion USA Inc.1$18
Sanofi-aventis U.S. LLC1$17
Hologic Sales And Service, LLC1$16
Ironwood Pharmaceuticals, Inc1$16
Exact Sciences1$15
Aimmune Therapeutics, Inc.1$15
Smith+Nephew1$15
LEO Pharma Inc.1$14
Phathom Pharmaceuticals, Inc.1$13
Currax Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,109 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,452,583
Medicare patients
176
Services billed
138,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmvuttraVutrisiran Sodium14$1,630,425
KrystexxaPegloticase17$907,864
CerezymeImiglucerase12$599,534
OcrevusOcrelizumab14$476,555
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5031$466,988
RituxanRituximab26$444,973
MounjaroTirzepatide399$425,735
OnpattroPatisiran Sodium,lipid Complex13$383,533
OrenciaAbatacept/Maltose71$360,624
LeqvioInclisiran Sodium86$272,618
RemicadeInfliximab28$212,677
TrulicityDulaglutide112$211,663
Kesimpta PenOfatumumab24$207,584
Dupixent SyringeDupilumab50$191,498
JardianceEmpagliflozin127$184,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alnylam Pharmaceuticals Inc.Amvuttra, Onpattro$272$2,013,95827 claims
AmgenKrystexxa$393$907,86417 claims
Lilly USA, LLCMounjaro, Trulicity$443$637,398511 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$40$466,98831 claims
NovartisLeqvio, Sandostatin Lar Depot, Entresto$295$364,956127 claims
PfizerInflectra, Eliquis, Nurtec Odt$291$273,717104 claims
AbbVieDalvance, Vraylar, Linzess$2,623$262,393116 claims
Boehringer IngelheimJardiance$121$184,282127 claims
GSKTrelegy Ellipta, Benlysta$88$180,747125 claims
Novo NordiskOzempic$346$112,49393 claims
AstraZenecaSaphnelo, Farxiga$216$109,43443 claims
Eisai Inc.Leqembi$25$101,56452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Hartsville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →